On Wednesday, September 13, 2017, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) supported, by unanimous votes of 11-Yes to 0-No, with no abstentions, the safety and effectiveness of Zoster Vaccine Recombinant, Adjuvanted, by GlaxoSmithKline Biologicals (GSK). The proposed trade name is Shingrix.
Back to All Events
Earlier Event: September 11Pediatric Advisory Committee
Later Event: September 14Anesthetic and Analgesic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee